Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

@article{Kim2014CombinationTW,
  title={Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.},
  author={Harrison Kim and Sharon L. Samuel and Guofu Zhai and Samir Rana and Marie Taylor and Heidi R. Umphrey and Denise K. Oelschlager and Donald J Buchsbaum and Kurt R Zinn},
  journal={Cancer biology & therapy},
  year={2014},
  volume={15 8},
  pages={
          1053-60
        }
}
TRA-8, a monoclonal antibody targeting death receptor, has demonstrated high therapeutic effect for triple negative breast cancer (TNBC) in preclinical models. Tamoxifen, the standard of care for ERα-positive breast cancer, induces apoptosis via ERβ, which commonly presents in TNBC cells. The current study investigates the combination effects of TRA-8 and tamoxifen for TNBC. In vitro assays were implemented with two ERβ-positive TNBC cell lines, SUM159 and 2LMP, and in vivo therapy studies were… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Similar Papers

Loading similar papers…